---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-190147"
form_type: "8-K"
ticker: "VIR"
cik: "0001706431"
company_name: "Vir Biotechnology, Inc."
filed_at: "2023-07-20T23:59:59+00:00"
generated_at: "2026-06-13T05:39:29.562592+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Vir Bio Phase 2 flu prevention trial misses endpoints; cash ~$1.9B

## Summary
- Phase 2 PENINSULA trial of VIR-2482 did not meet primary or secondary efficacy endpoints for preventing symptomatic influenza A.
- Highest dose (1,200 mg) showed non-statistically significant 16% reduction in protocol-defined influenza A illness vs placebo.
- Secondary endpoint (CDC-defined ILI) showed 57% reduction, but not statistically significant (95% CI -2.51 to 82.15).
- VIR-2482 was generally well tolerated; no safety signals identified; ~3,000 participants enrolled.
- Cash, cash equivalents and investments were approximately $1.9 billion as of June 30, 2023.

## SEC filing metadata
- accession: 0001193125-23-190147
- form_type: 8-K
- ticker: VIR
- cik: 0001706431
- company_name: Vir Biotechnology, Inc.
- filed_at: 2023-07-20T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1706431/000119312523190147/0001193125-23-190147-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1706431/000119312523190147/d517183d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-190147
- JSON: https://secwatch.observer/filing/0001193125-23-190147.json
- Plain text: https://secwatch.observer/filing/0001193125-23-190147.txt

## Key facts
- Earnings Releases
  Vir Biotechnology, Inc. reported preliminary financial results for the quarter ended June 30, 2023.
  - Period: the quarter ended June 30, 2023
  - Result: preliminary results
  source text: Although it has not finalized its full financial results for the quarter ended June 30, 2023, Vir Biotechnology, Inc. (the “Company”) disclosed in a press release on July 20, 2023, that it had cash, cash equivalents and investments of approximately $1.9 billion as of June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1706431/000119312523190147/0001193125-23-190147-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.